Polsinelli’s pharmacy law practice is recognized as one of the nation’s premier pharmacy law practices. Our attorneys advise pharmacy clients and pharmacy professionals on regulations associated with drug distribution from manufacturers, wholesalers and pharmacies to hospitals, physicians, clinics, other facilities and ultimately to patients. We represent national and regional pharmacy chains, home and alternate site infusion pharmacies, specialty pharmacies, mail-order pharmacies, independent retail pharmacies, long-term care pharmacies, hospitals and retailers with pharmacy operations,  group purchasing organizations, pharmacy services administrative organizations, pharmacy benefit managers, and technology vendors supporting pharmacy operations. Our clients include 340B pharmacies and related contract pharmacies. 

Polsinelli’s attorneys advise its pharmacy clients in matters relating to business organization, commercial contracting, mergers, acquisitions and divestitures, reimbursement, third-party payor audits (including state audits), allegations of diversion, pharmacy compounding matters, federal and state anti-kickback issues, and privacy and security issues.  

Polsinelli’s regulatory attorneys routinely represent its pharmacy clients before state and federal agencies including state boards of pharmacy, Food and Drug Administration (FDA), Drug Enforcement Administration (DEA), Center for Medicare and Medicaid Services (CMS), Health Resource and Services Administration (HRSA), Office of the Inspector General (OIG) and Department of Justice (DOJ).  

Related Capabilities
Health Care
Publications
All Publications
NYBOP May 2026 Deadline Is Fast Approaching: Do Your Pharmacy and Pharmacists Have the Right Licenses?
Key Takeaways: The New York State Board of Pharmacy (NYBOP) issued guidance in December 2025 requiring licensure both for pharmacies and for each individual pharmacist participating in shared pharmacy services arrangements when servicing New York patients. Nonresident pharmacy registration alone is no longer sufficient to satisfy shared services compliance. While this requirement becomes effective May 22, 2026, organizations should not delay taking action now. A proactive assessment and timely remediation of any licensure gaps will be critical to ensuring compliance moving forward. What Organizations Should Be Doing Now Evaluate your shared services model to identify where operations may be impacted; Confirm that all pharmacists supporting or involved in New York operations, including remote personnel, hold appropriate licensure and identify any gaps; Implement proactive compliance measures for any
Read More
Missouri Attorney General Files Suit Against Pharmacy Benefit Managers and Drug Manufacturers for Alleged Insulin Pricing Scheme
Key Takeaways The Missouri AG filed suit in St. Louis County Circuit Court against several PBMs and drug manufacturers, alleging they conspired to manipulate Missouri’s health care market and unlawfully drive up insulin prices. The AG’s office seeks restitution and damages for affected consumers, injunctive relief to halt the alleged practices and a finding of unjust enrichment by the Defendants. Missouri Attorney General Catherine Hanaway recently filed suit against a number of Pharmacy Benefit Manager (PBM) companies and drug manufacturers (collectively, the Defendants) doing business in Missouri. According to the Missouri Attorney General's (AG) office, the Defendants have allegedly manipulated Missouri's health care markets, resulting in a significant increase in the price of insulin medication. The Missouri AG's lawsuit, filed in St. Louis County
Read More